8:49 AM
Leo Group India
| ||
| Oramed Pharmaceuticals Completes $5.6 Million Funding to Advance Clinical ... Sacramento Bee Oramed Pharmaceuticals Inc. (OTCBB:ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it has completed a capital raise of $4,973,075, net of finder's fee, priced at $0.37 per unit. Each unit includes one ... See all stories on this topic » | ||
| Catalyst Pharmaceutical Partners Announces Automatic Conversion of $5 ... NASDAQ CORAL GABLES, Fla., Dec. 11, 2012 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced that it has issued 6,666,667 shares (the "Shares") of its authorized but unissued common stock to BioMarin ... See all stories on this topic » | ||
| SOMAXON PHARMACEUTICALS, INC. : Pernix Therapeutics Announces ... 4-traders Pernix Therapeutics Holdings, Inc. ("Pernix") (NYSE MKT: PTX) and Somaxon Pharmaceuticals, Inc. ("Somaxon") (NASDAQ: SOMX) today announced that they have entered into a definitive merger agreement for Pernix to acquire Somaxon in a stock-for-stock ... See all stories on this topic » | ||
| Beyond The Fiscal Cliff, Pharmaceutical Innovation Is The Key To Long-Term ... Forbes When you look beyond the current "fiscal cliff" brinksmanship, the long-term budget deficit will depend in large part on two key trendlines: health care costs and economic growth. I'd like to explain how pharmaceutical innovation can be a key positive ... See all stories on this topic » | ||
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED : Teva and Xenon Announce ... 4-traders Teva Pharmaceutical Industries Ltd (NYSE: TEVA) and Xenon Pharmaceuticals Inc. (Xenon) announced today that they have entered into a collaborative development and exclusive worldwide license for XEN402. XEN402 is currently in clinical development ... See all stories on this topic » | ||
| Biogen Idec and Isis Pharmaceuticals Announce Collaboration For Antisense ... Pharmaceutical Processing Biogen Idec and Isis Pharmaceuticals, Inc. have entered into a global collaboration agreement under which the companies will discover and develop antisense drugs against three undisclosed targets to treat neurological or neuromuscular disorders. Biogen ... See all stories on this topic » | ||
| ACETO Subsidiary, Rising Pharmaceuticals, Launches First Generic Version of ... Equities.com PORT WASHINGTON, N.Y., Dec. 11, 2012 (GLOBE NEWSWIRE) -- ACETO Corporation (Nasdaq:ACET), a global leader in the marketing, sale and distribution of products for Human Health, Pharmaceutical Ingredients and Performance Chemicals, today ... See all stories on this topic » | ||
| Centralized Portfolio Management Teams Guide Decisions Amid ... The Herald | HeraldOnline.com RESEARCH TRIANGLE PARK, N.C. — More than three-quarters (77%) of surveyed pharmaceutical companies have created dedicated portfolio management teams, according to a study by Cutting Edge Information. Furthermore, 79% of these dedicated ... See all stories on this topic » | ||
| SUCAMPO PHARMACEUTICALS, INC. : Sucampo Receives $15 Million ... 4-traders Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) (SPI) today announced that its subsidiary, Sucampo AG, has received a $15 million milestone payment from Abbott's (NYSE: ABT) subsidiary, Abbott Japan Co., Ltd. (Abbott), pursuant to the existing license, ... See all stories on this topic » | ||
| Norwich Pharmaceuticals Awarded Chenango County, NY Manufacturer of the ... Pharmaceutical Processing Norwich Pharmaceuticals, a provider of full-service contract development and manufacturing services for the pharmaceutical and biotech industry, announced today that the company has been recognized as Manufacturer of the Year by the Chenango County ... See all stories on this topic » |
Tip: Use site restrict in your query to search within a site (site:nytimes.com or site:.edu). Learn more.
Delete this alert.
Create another alert.
Manage your alerts.
0 comments:
Post a Comment